Konstantinos Leventakos, MD, discusses the impact of the PACIFIC trial on the stage III non–small cell lung cancer treatment, as well as what questions still remain.
Konstantinos Leventakos, MD
Advertisement
Articles by Konstantinos Leventakos, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
Precision Advances Have Transformed Lung Cancer Care, But Key Barriers Persist
4
FDA Awards Orphan Drug Designation to Enzomenib for ALL
5